HSP90AA1 and hepatocellular carcinoma: In order to further reveal the relevant biological mechanism, RNA-seq, and ACRIP-Seq were performed to identify HSP90AA1 as an intermediate molecular target for promoting drug resistance in ERS HCC during NAT10-mediated acetylation.